statistiche ricercatore

Continente	#
NA - Nord America	992
EU - Europa	753
AS - Asia	452
SA - Sud America	117
AF - Africa	18
Continente sconosciuto - Info sul continente non disponibili	1
Totale	2.333

Nazione	#
US - Stati Uniti d'America	978
RU - Federazione Russa	183
CN - Cina	132
IT - Italia	130
GB - Regno Unito	128
SG - Singapore	111
IE - Irlanda	109
BR - Brasile	93
VN - Vietnam	83
SE - Svezia	45
FR - Francia	32
UA - Ucraina	31
DE - Germania	30
HK - Hong Kong	30
FI - Finlandia	22
IN - India	17
KR - Corea	15
ZA - Sudafrica	13
BD - Bangladesh	12
BE - Belgio	11
CA - Canada	10
AR - Argentina	8
TR - Turchia	8
ID - Indonesia	7
NL - Olanda	6
AT - Austria	5
ES - Italia	5
JP - Giappone	5
SA - Arabia Saudita	5
AE - Emirati Arabi Uniti	4
AZ - Azerbaigian	4
CH - Svizzera	4
PK - Pakistan	4
PY - Paraguay	4
CZ - Repubblica Ceca	3
EC - Ecuador	3
IQ - Iraq	3
KZ - Kazakistan	3
MX - Messico	3
PL - Polonia	3
UY - Uruguay	3
VE - Venezuela	3
CO - Colombia	2
EG - Egitto	2
NG - Nigeria	2
UZ - Uzbekistan	2
A2 - ???statistics.table.value.countryCode.A2???	1
AL - Albania	1
BA - Bosnia-Erzegovina	1
CR - Costa Rica	1
GR - Grecia	1
HR - Croazia	1
IL - Israele	1
IR - Iran	1
LB - Libano	1
LT - Lituania	1
MA - Marocco	1
MY - Malesia	1
NO - Norvegia	1
NP - Nepal	1
PE - Perù	1
TH - Thailandia	1
TW - Taiwan	1
Totale	2.333

Nome	#
Molecular insights to the bioactive form of BV02, a reference inhibitor of 14-3-3σ protein-protein interactions	291
Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform	287
Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections	287
Chroman-4-one derivatives targeting pteridine reductase 1 and showing anti-parasitic activity	274
Profiling of flavonol derivatives for the development of antitrypanosomatidic drugs	270
Comparative mapping of on-targets and off-targets for the discovery of anti-trypanosomatid folate pathway inhibitors	236
Development of flavonol and flavanone derivatives as anti-trypanosomatidic drugs	228
Repurposing the Trypanosomatidic GSK Kinetobox for the Inhibition of Parasitic Pteridine and Dihydrofolate Reductases	180
Crystal structure of the ternary complex of Leishmania major pteridine reductase 1 with the cofactor NADP+/NADPH and the substrate folic acid	166
Multitarget, selective compound design yields potent inhibitors of a Kinetoplastid Pteridine Reductase 1	162
Totale	2.381

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	127	4	19	9	14	11	4	6	6	8	10	11	25
2022/2023	148	8	11	23	11	17	34	5	12	17	2	6	2
2023/2024	192	7	7	16	13	9	52	60	1	3	7	0	17
2024/2025	306	10	13	29	14	36	27	9	10	33	12	35	78
2025/2026	932	60	129	119	151	165	22	75	20	36	54	33	68
2026/2027	20	20	0	0	0	0	0	0	0	0	0	0	0
Totale													2.381